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Is Patient Frailty the
Unmeasured Confounder That
Connects Subacute Stent
Thrombosis With Increased
Periprocedural Bleeding and
Increased Mortality?*
Lloyd W. Klein, MD, Carlos Arrieta-Garcia, MD
Chicago, Illinois
Stent thrombosis is an uncommon but serious complication
of coronary artery stenting that frequently presents as death
or nonfatal myocardial infarction (MI), often with ST-
segment elevation. Apprehension regarding stent thrombo-
sis influences which patients are candidates for coronary
interventions and alters the strategy by which stents are
deployed (1). Adjunctive pharmacology is profoundly al-
tered due to these potential consequences: both the routine
administration and duration of dual antiplatelet therapy
(DAT) and other anticoagulants center on the prevention of
stent thrombosis (2).
See page 1752
The generally held conception of the equilibrium between
hemostasis and intravascular thrombosis is that the patients
who bleed are the same patients who develop stent throm-
bosis and, hence, have a higher rate of mortality, particularly
in the setting of an acute ST-segment elevation myocardial
infarction (STEMI). However, recent findings of the
HORIZONS-AMI (Harmonizing Outcomes with Revas-
cularization and Stents in Acute Myocardial Infarction)
trial, published in this issue of the Journal (3), raise serious
doubts regarding the completeness of this explanation to
characterize the relation among mortality, stent thrombosis,
and bleeding. The scenario of DAT cessation is actually
rarely encountered in acute stent thrombosis, but is common
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disclose.in late stent thrombosis. The inability to elucidate the
operational sequence of events or clarify the association of
bleeding, stent thrombosis distant from the periprocedural
bleeding, and mortality suggests that the data collected in
clinical trials and registries cannot fully account for these
relationships. Therefore, an unmeasured confounder must
be involved, which either completely, or in combination
with other factors, accounts for these connections. The
possibility that patient frailty is the missing variable should
be tested prospectively in future studies.
Early versus late stent thrombosis: pathogenesis. The
causes of early and late stent thrombosis are disparate.
When large retrospective analyses and randomized clinical
trials are analyzed for risk factors that predispose to stent
thrombosis, there are recurring patient-specific and
procedure-related factors that seem to convey greater risk
(4–7) (Table 1). Early and late stent thrombosis shares a
common final pathway: poor neointimal coverage leading to
a thromboembolic milieu, which in turn leads to activation
of platelets and thrombus formation.
Relative mortality of stent thrombosis presentations.
Stent thrombosis is associated with increased mortality,
whether early or late (7). It might be expected that late stent
thrombosis would be associated with higher mortality, as it
occurs out of hospital and unrelated to an index STEMI.
However, acute stent thrombosis carries a higher risk (5).
Another study showed no difference in death at 1 year
between early versus late stent thrombosis, but the compos-
ite endpoint of death, MI, and recurrent stent thrombosis
was higher in early stent thrombosis (8). Moreover, patients
with early stent thrombosis had higher rates of cardiogenic
shock (39.2% vs. 20%, p  0.042), suggesting a more dire
presentation.
Major bleeding increases mortality. Excess bleeding in
acute coronary syndromes is associated with higher mortality.
In a study of 30,000 patients at 350 hospitals (9), patients with
igher rates of major bleeding had higher mortality. Eikel-
oom et al. (8) found that patients with major bleeding
xperienced a 5-fold higher incidence of death during the first
0 days and 50% higher risk between 30 days and 6 months.
The controversial question is whether relatively minor epi-
odes of bleeding are actually responsible for later mortality.
he most obvious potential relationship is if bleeding leads to
arly cessation of DAT. However, there are other potential
echanisms that have been considered. Experimental data
uggest that increased synthesis of erythropoetin in response to
nemia caused by bleeding might sustain a systemic prothrom-
otic state beyond the acute phase by causing platelet activation
nd inducing plasminogen activator 1 (11).
Finally, several investigators have noted a relationship
ith blood transfusions. In a retrospective analysis of
on-STEMI patients, Rao et al. (10) showed that transfu-
ion was associated with increased adverse events and
0-day mortality.
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May 15, 2012:1760–2 Patient Frailty and Subacute Stent ThrombosisThe HORIZONS-AMI trial. The HORIZONS-AMI
trial previously reported that patients with major bleeding
after primary percutaneous coronary intervention (PCI) have
significantly increased 3-year rates of morbidity and mortality
(13). The survival curves show a rapid early separation in
curves, which continues to diverge throughout the 36-month
period. Landmark analysis shows 3 separate statistically signif-
icant breakpoints: at 30 days, 12 months, and 3 years. When
the hazard ratios for 3-year mortality are compared, major
bleeding, stent thrombosis, and age are the 3 most powerful
independent predictors.Whether bleeding is the primary event
that drives mortality or just a surrogate marker that denotes a
sicker population is a crucial point of contention (14), especially
because it is difficult to explain how bleeding, considered to be
an acute, short-lived, “reversible” event, can lead to increased
mortality years after hospital discharge.
Dangas et al. (3) further explore this surprising observa-
tion. Mortality at 1 year in patients with in-hospital stent
thrombosis was 27.8% compared with 10.8% in patients
with late stent thrombosis (p  0.007). Despite the obser-
vation that the rate of major bleeding was higher in patients
who experienced in-hospital stent thrombosis (21.2% vs. 6%
p  0.006), major bleeding was not an independent pre-
dictor of mortality at 1 year (see Table 5 in Dangas et al.
[3]). By multivariable analysis, 1-year mortality was signif-
icantly increased in patients with in-hospital compared with
out-of-hospital stent thrombosis (adjusted hazard ratio:
4.69, 95% confidence interval: 2.00 to 11.01, p 0.01). The
cute stent thrombosis group had a mortality of 7.1%, the
ubacute thrombosis group had a mortality of 50% in-
ospital and 27.6% out-of-hospital, mortality was 3.3% in
he late stent thrombosis group, and mortality was 8.0% the
ery late stent thrombosis group; hence, it was the subacute
Mechanisms of Early and Late Stent ThrombosisTable 1 Mechanisms of Early and Late Sten
Early Stent Thromb
Stent factors Incomplete stent apposition
Stent undersizing or underexpan
Post-PCI minimal lumen CSA
5 mm2
Patient factors Bleeding
Age
Frailty
Lesion characteristics Local thrombus
Impaired distal flow due to dista
Presence of vulnerable plaque a
stent placement
ACS  acute coronary syndrome(s); CSA  cross-sectional area; D
percutaneous coronary intervention; STEMI  ST-segment elevation mhrombosis cohorts, in- and out-of-hospital, with the worstoutcomes. Two-thirds of the stent thromboses occurred
after hospital discharge. The breakdown of stent thrombosis
timing as in- versus out-of-hospital, when combined with
the Academic Research Consortium definitions (see Fig. 3
in Dangas et al. [3]), shows that even in the subacute stent
thrombosis group, mortality was highest in patients still
hospitalized. Figure 3 (3) further illustrates that with out-
of-hospital stent thrombosis, mortality was highest if the
event occurred within 30 days after the index procedure.
The HORIZONS-AMI trial was unique in that rates of
DAT remained high throughout the follow-up period, and
thus any analysis in respect to bleeding/stent thrombosis are
independent of this factor. Age was not a predictive factor.
There does seem to be a confusing difference between
the 2 publications, in that a univariate, unadjusted associ-
ation between bleeding in-hospital and subsequent stent
thrombosis within the 3-year follow-up period of the
HORIZONS-AMI trial was originally reported (13).
However, in the current paper (3), after multivariate adjust-
ment, bleeding was not associated with in-hospital or
out-of-hospital stent thrombosis. The authors clarify this
problem in the discussion; the key point is that the rela-
tionship between bleeding and subsequent stent thrombosis
is not necessarily causal.
Implications. These new observations are inconsistent
with current characterizations of the relation between mor-
tality, stent thrombosis, and bleeding. Specifically, there is
no known pathophysiologic mechanism that explains how
periprocedural bleeding and 1- and 3-year mortality can be
related, or that explains exceptionally high mortality in
subacute stent thrombosis. Although bleeding risk in acute
coronary syndromes can be predicted (14,15), there is no
known connection with risk for stent thrombosis. Either
ombosis
Late Stent Thrombosis
Hypersensitivity to drug coating
Incomplete endothelialization
Stent design
Covered stents
PCI for ACS/STEMI
DM
Renal failure
Impaired LV function
Premature cessation of antiplatelet therapy
Aspirin nonresponsiveness
Clopidogrel nonresponsiveness
GP IIb/IIIa inhibitors
Malignancy
Saphenous vein grafts
olization
ite of
Lesion/stent length
Vessel/stent diameter
Complex lesions (bifurcation lesion,
chronic total lesions)
Stasis
Stenting over a side branch
iabetes mellitus; GP  glycoprotein; LV  left ventricular; PCI 
ial infarction.t Thr
osis
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information that ties together the clues already identified.
We believe it is likely that the usual variables collected in
clinical trials and interventional registries are not sufficiently
powerful to explain these associations, and suggest that an
unmeasured confounder must be involved. Although cessa-
tion of DAT and transfusions may be contributory, they
cannot explain the observations made in the HORIZONS-
AMI trial. Age and factors related to risk and extent of
disease may also be related, but are inadequate to explain the
findings in isolation. There is some common systemic factor
at play that is upsetting the fragile balance between clotting
and bleeding, as that is the most apparent pathophysiologic
connection among these conditions.
Patient frailty is the variable most likely to be the missing
confounder. It is intuitive that the fragile balance sought
between thrombosis and bleeding is most apt to be easily
disrupted by acute illness in a delicate, less active, less vigorous
person. This makes sense both from a technical/procedural
viewpoint as well as from the pharmacology aspect. Even
among older patients (65 years of age) there are subgroups
with different cardiovascular outcomes after percutaneous re-
vascularization. Using a frailty index, Singh et al. (14) were able
to identify a subgroup at higher risk: at 35-month follow-up,
28% of patients identified as frail had died compared with 6%
of nonfrail patients. Adding frailty, quality of life, and comor-
bidity to the Mayo Clinic PCI Risk Score conferred a discern-
ible improvement to predict death and death/MI.
Obviously, a fundamental problem lies in how to objec-
tively evaluate frailty. Gharachololou et al. (16) combined
the Fried criteria to assess frailty, which includes assessment
of 5 items: unintended weight loss (10 lb in the preceding
year), exhaustion (by 2 questions), physical activity, time
required to walk 15 feet, and hand grip strength combined
with the Charlson index for comorbidity and the SF-36
questionnaire for quality of life. This approach was strongly
supported for elderly patients (17) but probably should be
included in a general assessment of all patients undergoing any
form of revascularization. A telephone interview was used to
assess cognition in STEMI patients (18). Cognitive impair-
ment was associated with less invasive care, lower rates of
referral and participation in cardiac rehabilitation, and worse
risk-adjusted 1-year survival. Frailty has also been identified as
a substantial issue in selection of patients for bypass surgery.
Conclusions. In the new analyses from the HORIZONS-
AMI trial, major in-hospital bleeding was associated with
increased mortality at times distant from the acute event.
This observation is incomprehensible without implicating a
previously unmeasured patient related factor that links with
the fragile balance of bleeding and thrombosis inherent in
interventional coronary procedures.
Future pharmacologic studies, PCI clinical trials, and regis-
tries such as the National Cardiovascular Data Registry should
be amended to include simple subjective clinical variables such
as frailty that have not been collected traditionally due to the
difficulty in their objective definition. It may be that theexplanation for an otherwise perplexing clinical observation is
discernible only at the most primitive level.
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